Loading

Please wait...

Oncaspar

Generic Name: pegaspargase (peg ah SPAR jase)
Brand Name: Oncaspar
Physician reviewed Oncaspar patient information - includes Oncaspar description, dosage and directions.
  • Prescription Settings
  • X
  • Local Pharmacy Pickup available at . Pick up your medication at any of our participating pharmacies.
  • Mail Order Home Delivery available at , the easiest way to receive your medications.
  • Learn more

Oncaspar Coupons & Prices

Set your location
for drug prices near you

Enter your zip code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Oncaspar is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Oncaspar is used in combination with other cancer medications to treat acute lymphoblastic leukemia. Oncaspar is also used to treat allergic Reactions to another cancer medication called asparaginase (Elspar). Oncaspar may also be used for purposes not listed in this medication guide. You should not use Oncaspar if you have ever received asparaginase and it caused pancreatitis, severe bleeding, a blood clot, or a severe allergic Reaction. Learn more

Pickup / Home Delivery

USARx offers multiple ways to purchase this medication. Choose the Best option for you!

  • Guaranteed Price
    Local Pharmacy Pickup

    Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.

  • 30-day supply
    90-day supply
    Mail Order Home Delivery

    The easiest way to receive your medications.

Oncaspar Side Effects

Note: This document contains side effect information about pegaspargase. Some of the dosage forms listed on this page may not apply to the brand name Oncaspar.

For the Consumer

Applies to pegaspargase: parenteral injection

Side effects include:

Hypersensitivity reactions, coagulopathy, hyperglycemia, elevated serum transaminase concentrations, hyperbilirubinemia, pancreatitis, CNS thrombosis. No apparent difference in adverse effects following IV versus IM administration.

For Healthcare Professionals

Applies to pegaspargase: injectable solution

General

The most commonly reported side effects were elevated transaminases and clinical allergic reactions to asparaginase (including bronchospasm, hypotension, laryngeal edema, local erythema or swelling, systemic rash, and urticaria).

Hypersensitivity

Very common (10% or more): Hypersensitivity, urticaria, anaphylactic reaction

Nervous system

Common (1% to 10%): Central nervous system thrombosis/hemorrhage, seizure, peripheral motor neuropathy, syncope

Rare (less than 0.1%): Posterior reversible leukoencephalopathy syndrome

Frequency not reported: Somnolence, tremor

Cardiovascular

Common (1% to 10%): Thrombosis, embolism

Gastrointestinal

Very common (10% or more): Pancreatitis, diarrhea, abdominal pain, nausea

Common (1% to 10%): Vomiting, stomatitis, ascites

Rare (less than 0.1%): Pancreatitis necrotizing, pancreatitis hemorrhagic

Frequency not reported: Pancreatic pseudocyst, parotitis

Hematologic

Very common (10% or more): Febrile neutropenia

Common (1% to 10%): Coagulopathy (prolonged prothrombin time or partial thromboplastin time; or hypofibrinogenemia), anemia

Frequency not reported: Bone marrow failure

Hepatic

Very common (10% or more): Elevated transaminases

Common (1% to 10%): Hyperbilirubinemia, hepatotoxicity, fatty liver

Rare (0.01% to 0.1%): Hepatic necrosis, jaundice, cholestasis, hepatic failure

Metabolic

Common (1% to 10%): Hyperglycemia, weight decreased, decreased appetite

Frequency not reported: Glucose intolerance, hyperlipidemia, hypercholesterolemia, diabetic ketoacidosis, hypoglycemia

Immunologic

Common (1% to 10%): Infections, sepsis

Musculoskeletal

Common (1% to 10%): Pain in extremities

Psychiatric

Frequency not reported: Confusion

Respiratory

Common (1% to 10%): Hypoxia

Other

Frequency not reported: Pyrexia

Renal

Frequency not reported: Acute renal failure

Dermatologic

Very common (10% or more): Rash

Frequency not reported: Toxic epidermal necrolysis (TEN), cerebrovascular accident, hemorrhage, superior sagittal sinus thrombosis

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Oncaspar (www.drugs.com/mtm/oncaspar.html).